04:56 AM EDT, 10/31/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) reported fiscal Q2 core earnings Thursday of 134 Japanese yen ($0.88) per share, up from 111 yen a year earlier.

Analysts' estimates were not readily available for comparison.

Revenue for the quarter ended Sept. 30 was 1.176 trillion yen, compared with 1.043 trillion yen a year earlier.

Analysts surveyed by Capital IQ expected 1.079 trillion yen.

The company raised its outlook for the fiscal year ending March 31, 2025, and now expects 456 yen in core EPS, from 431 yen previously.

Meanwhile, revenue for the fiscal year is now projected to be 4.480 trillion yen, compared with the prior outlook of 4.350 trillion yen. Analysts surveyed by Capital IQ expect 4.433 trillion yen.